Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.41 |
| ▸ | TDP2 | O95551 | 6/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104806 | 0.80 | AHR (0.61) | AHR | |
| SCHEMBL20605163 | 0.77 | KDM4E (0.41) | AHRPDE10AKDM4EALDH1A1MAPK1 | |
| SCHEMBL30842034 | 0.77 | CYP11B1 (0.46) | AHR | |
| SCHEMBL9105398 | 0.77 | AHR (0.41) | AHRKDM4EALDH1A1 | |
| SCHEMBL16979292 | 0.77 | KDM4E (0.40) | AHRTDP2PDE10AKDM4EALDH1A1 | |
| SCHEMBL31456654 | 0.77 | AHR (0.41) | AHR | |
| SCHEMBL30601219 | 0.76 | AHR (0.74) | AHRTDP2PDE10ANPSR1 | |
| Hydrochloric Acid SCHEMBL16320639 | 0.76 | AHR (0.40) | AHRKDM4EALDH1A1 | |
| SCHEMBL31310189 | 0.74 | AHR (0.36) | AHRPDE10AKDM4EALDH1A1MAPK1 | |
| SCHEMBL21069633 | 0.73 | AHR (0.41) | AHRTDP2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688777-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024200308-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2024-10-03 | — | — | WO | disclosed |
| EP-4434987-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2024-09-25 | — | — | EP | disclosed |
| WO-2019057946-A1 | MULTI-CYCLIC AROMATIC COMPOUNDS AS FACTOR D INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019057946-A1 | MULTI-CYCLIC AROMATIC COMPOUNDS AS FACTOR D INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-28 | — | — | WO | disclosed |
| EP-2855455-B1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| EP-2855455-B1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2855455-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013178572-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013178572-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | PDE3A, PDE3B, PDE5A | AHR 4145/4885TDP2 317/4885PDE10A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.